Twinbeech Capital LP Revance Therapeutics, Inc. Transaction History

Twinbeech Capital LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $432,484 - $833,705	74,438 New	74,438 $654,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $1.79 Million - $2.73 Million	72,482 Added 73.45%	171,166 $4.33 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.26 Million - $2.43 Million	-68,798 Reduced 41.08%	98,684 $3.18 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $3.07 Million - $5.13 Million	167,482 New	167,482 $3.09 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.